Latest & greatest articles for calcium

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on calcium or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on calcium and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for calcium

161. Intravenous Calcium and Magnesium for Oxaliplatin-Induced Sensory Neurotoxicity in Adjuvant Colon Cancer: NCCTG N04C7 Full Text available with Trip Pro

Intravenous Calcium and Magnesium for Oxaliplatin-Induced Sensory Neurotoxicity in Adjuvant Colon Cancer: NCCTG N04C7 Cumulative sensory neurotoxicity (sNT) is the dose-limiting toxicity of oxaliplatin, which commonly leads to early discontinuation of oxaliplatin-based therapy in the palliative and adjuvant settings. In a nonrandomized, retrospective study, intravenous (IV) calcium/magnesium (Ca/Mg) was associated with reduced oxaliplatin-induced sNT.Patients with colon cancer undergoing (...) adjuvant therapy with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX) were randomly assigned to Ca/Mg (1g calcium gluconate plus 1g magnesium sulfate pre- and post-oxaliplatin) or placebo, in a double-blinded manner. The primary end point was the percentage of patients with grade 2 or greater sNT at any time during or after oxaliplatin-based therapy by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE; version 3) criteria. An oxaliplatin-specific sNT

2011 EvidenceUpdates Controlled trial quality: uncertain

162. Phoslyra (calcium acetate)

Phoslyra (calcium acetate) Drug Approval Package: Phoslyra (calcium acetate) NDA #022581 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Phoslyra (calcium acetate) 667 mg/ 5mL oral solution Company: Fresenius Medical Care North America Application No.: 022581 Approval Date: 04/18/2011 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF

2011 FDA - Drug Approval Package

163. Calcium and vitamin D: no prescribing changes

Calcium and vitamin D: no prescribing changes Calcium and vitamin D: no prescribing changes - GOV.UK GOV.UK uses cookies to make the site simpler. or Search Calcium and vitamin D: no prescribing changes Studies of cardiovascular risk don’t support prescribing changes. Published 11 December 2014 From: Therapeutic area: , Article date: October 2011 A research article in 2010 by Bolland and colleagues seemed to show that calcium supplements without coadministered vitamin D are associated (...) with a modest increased risk of myocardial infarction (MI, hazard ratio [HR] 1.31 [95% CI 1.02–1.67]; p=0.035). Non-significant increases occurred in the incidence of stroke and death; the risk for the composite endpoint (MI, stroke, or sudden death) was of borderline significance (HR 1.18 [1.00–1.39], p=0.057). The researchers have recently published a reanalysis of data from a large randomised controlled trial (the Women’s Health Initiative study—WHI), and a further meta-analysis of trials of calcium

2011 MHRA Drug Safety Update

164. Cost-effectiveness analysis regarding postoperative administration of vitamin-D and calcium after thyroidectomy to prevent hypocalcaemia

Cost-effectiveness analysis regarding postoperative administration of vitamin-D and calcium after thyroidectomy to prevent hypocalcaemia Cost-effectiveness analysis regarding postoperative administration of vitamin-D and calcium after thyroidectomy to prevent hypocalcaemia Cost-effectiveness analysis regarding postoperative administration of vitamin-D and calcium after thyroidectomy to prevent hypocalcaemia Sanabria A, Dominguez LC, Vega V, Osorio C, Duarte D Record Status This is a critical (...) abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The study examined cost-effectiveness of routine postoperative administration of vitamin D or metabolites and calcium to reduce the incidence of hypocalcaemia after total thyroidectomy. The authors concluded that both

2011 NHS Economic Evaluation Database.

165. Systematic review: Vitamin D reduces the risk of falls in older adults compared with calcium or placebo

Systematic review: Vitamin D reduces the risk of falls in older adults compared with calcium or placebo Vitamin D reduces the risk of falls in older adults compared with calcium or placebo | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Vitamin D reduces the risk of falls in older adults compared with calcium or placebo Article Text Care of the older person Systematic review Vitamin D reduces the risk of falls in older adults compared with calcium

2011 Evidence-Based Nursing

166. Calcium Channel Blockers and Enamel Demineralization

Calcium Channel Blockers and Enamel Demineralization UTCAT845, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Patients On Calcium Channel Blockers Should Be Monitored For Enamel Demineralization Clinical Question In patients taking calcium channel blockers [for the treatment of hypertension, angina, tachycardia, etc], has demineralization of the enamel been seen to a degree that a remineralization regimen would (...) be indicated? Clinical Bottom Line Yes, in the cited study, a significantly increased number of patients who underwent calcium antagonist therapy exhibited signs of “decalcination” and and dental caries, but this is not yet grounds for prophylactic remineralization. (See Comments on the CAT below) Best Evidence (you may view more info by clicking on the PubMed ID link) PubMed ID Author / Year Patient Group Study type (level of evidence) #1) Ivanova/1999 100 taking calcium channel blocker vs. 60 not taking

2011 UTHSCSA Dental School CAT Library

167. Formocresol vs Direct Pulp Capping with Calcium Hydroxide in Primary Teeth

Formocresol vs Direct Pulp Capping with Calcium Hydroxide in Primary Teeth UTCAT765, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Formocresol Vs Direct Pulp Capping with Calcium Hydroxide in Primary Teeth Clinical Question In children (4-5 years old) with carious primary molars, will the use of formocresol provide better long-term success with fewer side effects than traditional direct pulp capping with calcium (...) hydroxide? Clinical Bottom Line Formocresol is clinically successful and should be considered as an alternative to direct pulp capping with calcium hydroxide in carious primary molars. (See Comments on the CAT below) Best Evidence (you may view more info by clicking on the PubMed ID link) PubMed ID Author / Year Patient Group Study type (level of evidence) #1) Aminabadi/2010 120 teeth (84 children) Randomized Controlled Trial Key results The prevalence of side effects such as pain, sensitivity

2011 UTHSCSA Dental School CAT Library

168. Prognosis of MTA Apexification Versus Calcium Hydroxide Apexification

Prognosis of MTA Apexification Versus Calcium Hydroxide Apexification UTCAT830, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Prognosis Of MTA Apexification Versus Calcium Hydroxide Apexification Clinical Question Does MTA apexification render better long-term prognosis than calcium hydroxide apexification for treatment of dens in dente in permanent dentition from children or adolescents? Clinical Bottom Line When (...) performed correctly, apexification with MTA and calcium hydroxide on permanent dentition with dens in dente and open apices both have similarly good long-term prognosis. However, given that MTA is more biocompatible and that it can be performed in one visit, MTA apexification is the treatment of choice. Best Evidence (you may view more info by clicking on the PubMed ID link) PubMed ID Author / Year Patient Group Study type (level of evidence) #1) Jaramillo/2006 Children to adolescent with dens in dente

2011 UTHSCSA Dental School CAT Library

169. Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): a randomised, parallel-group trial. (Abstract)

Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): a randomised, parallel-group trial. Short-term studies have suggested that the use of initial combination therapy for the control of blood pressure improves early effectiveness. We tested whether a combination of aliskiren and amlodipine is superior to each monotherapy in early control of blood pressure without excess of adverse events, and if initial control

2011 Lancet Controlled trial quality: predicted high

170. Effect of a high-calcium energy-reduced diet on abdominal obesity and cardiometabolic risk factors in obese Brazilian subjects (Abstract)

Effect of a high-calcium energy-reduced diet on abdominal obesity and cardiometabolic risk factors in obese Brazilian subjects Clinical trials designed to examine the effects of calcium supplementation on abdominal obesity have had ambiguous results.This study aimed to evaluate, during energy restriction, the effects of a high-calcium diet (HCD) on measures of abdominal obesity and cardiometabolic risk factors in Brazilian obese subjects of multiethnic origin.We conducted a randomised clinical (...) trial. Fifty obese subjects of both sexes, aged 22-55 years, with stable body weight and a low calcium intake were randomised into the following outpatient dietary regimens: (i) a low-calcium diet (LCD; < 500 mg/day) or (ii) a HCD [1200-1300 mg/day, supplemented with non-fat powdered milk (60 g/day)]. Both groups followed an energy-restricted diet (-800 kcal/day) throughout the study (16 weeks).Thirty-nine participants completed the study. After 16 weeks of energy restriction, a significant

2010 EvidenceUpdates Controlled trial quality: uncertain

171. Nonoptimal Lipids Commonly Present in Young Adults and Coronary Calcium Later in Life: The CARDIA (Coronary Artery Risk Development in Young Adults) Study. Full Text available with Trip Pro

Nonoptimal Lipids Commonly Present in Young Adults and Coronary Calcium Later in Life: The CARDIA (Coronary Artery Risk Development in Young Adults) Study. Dyslipidemia causes coronary heart disease in middle-aged and elderly adults, but the consequences of lipid exposure during young adulthood are unclear.To assess whether nonoptimal lipid levels during young adulthood cause atherosclerotic changes that persist into middle age.Prospective cohort study.4 cities in the United States.3258 (...) participants from the 5115 black and white men and women recruited at age 18 to 30 years in 1985 to 1986 for the CARDIA (Coronary Artery Risk Development in Young Adults) study.Low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol, triglycerides, and coronary calcium. Time-averaged cumulative exposures to lipids between age 20 and 35 years were estimated by using repeated serum lipid measurements over 20 years in the CARDIA study; these measurements were then related to coronary

2010 Annals of Internal Medicine

172. Coronary artery calcium score and risk classification for coronary heart disease prediction. Full Text available with Trip Pro

Coronary artery calcium score and risk classification for coronary heart disease prediction. The coronary artery calcium score (CACS) has been shown to predict future coronary heart disease (CHD) events. However, the extent to which adding CACS to traditional CHD risk factors improves classification of risk is unclear.To determine whether adding CACS to a prediction model based on traditional risk factors improves classification of risk.CACS was measured by computed tomography in 6814

2010 JAMA

173. A prospective randomized controlled trial of a bioresorbable calcium phosphate paste (alpha-BSM) in treatment of displaced intra-articular calcaneal fractures (Abstract)

A prospective randomized controlled trial of a bioresorbable calcium phosphate paste (alpha-BSM) in treatment of displaced intra-articular calcaneal fractures Displaced intra-articular calcaneal fractures are devastating injuries and pose a therapeutic challenge. The purpose of this study was to determine whether open reduction internal fixation (ORIF) plus an injectable bioresorbable calcium phosphate paste (alpha-BSM [bone substitute material]) is superior to ORIF alone in the treatment (...) degree) in alpha-BSM and ORIF and ORIF alone groups, respectively, (p = 0.05). There was no difference between the two groups in regards to secondary outcome measures of general health, limb specific function, and pain past 2 years.These results support the use of an injectable, in situ hardening calcium phosphate paste to fill the bone void after a displaced intra-articular calcaneal fracture. There was no impact on general health, limb specific function, and pain past 2 years and no associated

2010 EvidenceUpdates Controlled trial quality: uncertain

174. Safyral (drospirenone/ethinyl estradiol/levomefolate calcium tablets and levomefolate calcium tablets)

Safyral (drospirenone/ethinyl estradiol/levomefolate calcium tablets and levomefolate calcium tablets) Drug Approval Package: Safyral (drospirenone/ethinyl estradiol) NDA #022574 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Safyral (drospirenone/ethinyl estradiol/levomefolate calcium tablets and levomefolate calcium tablets) Company: Bayer HealthCare Pharmaceuticals Inc. Application No.: 022574 Approval Date: 12/16/2010 Persons with disabilities

2010 FDA - Drug Approval Package

175. Beyaz (drospirenone/ethinyl estradiol/levomefolate calcium and levomefolate calcium)

Beyaz (drospirenone/ethinyl estradiol/levomefolate calcium and levomefolate calcium) Drug Approval Package: Beyaz (drospirenone/ethinyl estradiol/levomefolate calcium and levomefolate calcium) NDA #022532 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Beyaz (drospirenone/ethinyl estradiol/levomefolate calcium and levomefolate calcium) tablets Company: Bayer HealthCare Pharmaceuticals Inc. Application No.: 022532 Approval Date: 09/24/2010 Persons

2010 FDA - Drug Approval Package

176. Calcium gluconate injection in small-volume glass containers: new contraindications due to aluminium exposure risk

Calcium gluconate injection in small-volume glass containers: new contraindications due to aluminium exposure risk Calcium gluconate injection in small-volume glass containers: new contraindications due to aluminium exposure risk - GOV.UK GOV.UK uses cookies to make the site simpler. or Search Calcium gluconate injection in small-volume glass containers: new contraindications due to aluminium exposure risk Aluminium can be leached from glass after contact with calcium gluconate solution (...) , leading to a risk of exposure to aluminium. Accumulation of aluminium might have adverse effects on bone mineralisation and neurological development in children and those with renal impairment. Calcium gluconate injection packed in small-volume glass containers is now contraindicated for use as repeated or prolonged treatment, including as an intravenous infusion, in children younger than 18 years and in patients with renal impairment. To limit the exposure of patients to aluminium, especially

2010 MHRA Drug Safety Update

177. Are calcium channel blockers superior to digoxin for controlling the ventricular rate in patients with recent onset atrial fibrillation?

Are calcium channel blockers superior to digoxin for controlling the ventricular rate in patients with recent onset atrial fibrillation? BestBets: Are calcium channel blockers superior to digoxin for controlling the ventricular rate in patients with recent onset atrial fibrillation? Are calcium channel blockers superior to digoxin for controlling the ventricular rate in patients with recent onset atrial fibrillation? Report By: Richard Parris - Locum Consultant Emergency Medicine Search checked (...) by Simon Clarke - Consultant Emergency Medicine Institution: Emergency Department Royal Bolton Hospital Date Submitted: 9th September 2004 Date Completed: 17th December 2009 Last Modified: 18th December 2009 Status: Green (complete) Three Part Question In a stable patient with [acute atrial fibrillation], is [treatment superior] with [calcium channel blockers or digoxin]? Clinical Scenario A 57 year old woman attends the Emergency Department with palpitations of uncertain duration. A diagnosis

2010 BestBETS

178. Systematic review: Calcium supplements increase risk of myocardial infarction

Systematic review: Calcium supplements increase risk of myocardial infarction Calcium supplements increase risk of myocardial infarction | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password (...) * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Calcium supplements increase risk of myocardial infarction Article Text Therapeutics Systematic review Calcium supplements increase risk of myocardial infarction Sonal Singh 1 , Curt D Furberg 2 Statistics from Altmetric.com Commentary on: Bolland MJ

2010 Evidence-Based Medicine

179. Remineralizing White Spot Lesions with Fluoride Alone or Fluoride and Casein Phosphopeptide-Amorphous Calcium Phosphate

Remineralizing White Spot Lesions with Fluoride Alone or Fluoride and Casein Phosphopeptide-Amorphous Calcium Phosphate UTCAT572, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Remineralizing White Spot Lesions With Fluoride Alone Or Fluoride And Casein Phosphopeptide-Amorphous Calcium Phosphate Clinical Question When there are white spot lesions present of enamel, does using fluoride alone or casein phosphopeptide (...) -amorphous calcium phosphate in conjunction with fluoride increase enamel remineralization? Clinical Bottom Line Casein phosphopeptide-amorphous calcium phosphate aids in fluoride uptake by enamel which accounts for more remineralization than just using fluoride alone. (See Comments on the CAT below) Best Evidence (you may view more info by clicking on the PubMed ID link) PubMed ID Author / Year Patient Group Study type (level of evidence) #1) Reynolds/2008 14 healthy participants Randomized comparative

2010 UTHSCSA Dental School CAT Library

180. Efficacy of Casein Phosphopeptide-Amorphous Calcium Phosphate(CPP-ACP)in Remineralizing Demineralized Tooth Structure

Efficacy of Casein Phosphopeptide-Amorphous Calcium Phosphate(CPP-ACP)in Remineralizing Demineralized Tooth Structure UTCAT573, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Efficacy of Casein Phosphopeptide-Amorphous Calcium Phosphate(CPP-ACP)in Remineralizing Demineralized Tooth Structure Clinical Question In a patient with dental caries, is casein phosphopeptide-amorphous calcium phosphate (CPP-ACP) effective (...) an improvement in subsurface remineralization in the group with CPP-ACP. Evidence Search Meta-Analysis, "Dental Caries"[Mesh] "casein phosphopeptide-amorphous calcium phosphate nanocomplex "[Substance Name] Comments on The Evidence A systematic review containing a comprehensive, detailed search for relevant trials (which were each assessed for validity) produced only one study comparing treatment with CPP-ACP to no treatment. This alone is not enough evidence to support the efficacy of CPP-ACP. However

2010 UTHSCSA Dental School CAT Library